Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown

Viatris Inc. (NASDAQ:VTRS) reported third-quarter 2024 total net sales of $3.74 billion. That’s down 5%, beating the consensus of $3.71 billion, but up about 3% on a divestiture-adjusted operational basis compared to third-quarter 2023 results.

The company reported divestiture-adjusted operational net sales growth across all segments.

Brands net sales reflect the expansion of the company’s portfolio in emerging markets and JANZ, as well as strong growth in Europe and Greater China. This was partially offset by unfavorable channel dynamics in North America and the impact of government price regulations in Japan and Australia. Brand sales fell 7% to $2.36 billion.

Generic ...